PYPD PolyPid Ltd.

PolyPid Ltd. is a clinical-stage pharmaceutical company focused on developing, manufacturing and commercializing novel, locally administered therapies using our transformational PLEX (Polymer-Lipid Encapsulation matriX) technology. The Company’s product pipeline candidates are designed to address unmet medical needs by pairing PLEX technology with approved pharmaceuticals which are delivered locally at predetermined release rates and durations over periods ranging from days to several months. PLEX technology has the potential to improve patient outcomes and lower the overall cost of treatment by enabling customizable, controlled local delivery of drugs, thereby addressing many of the shortcomings of systemic administration and existing localized delivery systems. PLEX technology may represent a paradigm shift in the treatment of several localized medical conditions, including infection, pain, inflammation and cancer.

As of 09/30/2022     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Israel
Country of incorporation:  
IPO date:  06/26/2020
Outstanding shares:  18,756,570
Average volume:  722,304
Market cap:   $23,070,581
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.78
PS ratio:   0.00
Return on equity:   -157.80%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy